REVOLUTION MEDICINES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.12 USD | +0.67% |
|
-1.20% | +46.86% |
| 08-15 | Revolution Medicines Insider Sold Shares Worth $716,389, According to a Recent SEC Filing | MT |
| 08-07 | Revolution Medicines Q2 Loss Narrows | MT |
Chart calendar Revolution Medicines, Inc.
a0564be08f382d48f98f1bceec61e3._d1VjblLXbEI8c17xhh6SYS_yFJdhNzfyOhDEEJe-mk.vOsD6os5DvBjgJQQ8XcAerGJsgI69YiooZ12Yww0lBi18A3F2zs0iHDBqg~8d919688cefb0a39a11827d963f18bac
Upcoming events on Revolution Medicines, Inc.
Past events on Revolution Medicines, Inc.
| 2024-08-07 16:30 | Q2 2024 Earnings Call |
| 2024-08-07 16:05 | Q2 2024 Earnings Release |
| 2024-07-15 08:00 | Business Update Call - RMC-6236 |
| 2024-06-20 10:30 | Annual General Meeting |
| 2024-06-12 14:40 | Goldman Sachs Global Healthcare Conference |
| 2024-05-08 16:30 | Q1 2024 Earnings Call |
| 2024-05-08 16:02 | Q1 2024 Earnings Release |
| 2024-04-16 15:30 | Stifel Virtual Targeted Oncology Days Conference |
| 2024-04-11 13:30 | Needham Healthcare Conference |
| 2024-04-09 17:35 | American Association for Cancer Research Meeting - Abstract Number: 6585 |
| 2024-04-09 16:00 | American Association for Cancer Research Meeting - RMC-6236, a RAS(ON) Multi-Selective Tri-Complex I |
| 2024-04-09 12:00 | American Association for Cancer Research Meeting - Abstract Number: 4709/2 |
| 2024-04-08 16:30 | American Association for Cancer Research Meeting - Abstract Number: 3340/28 |
| 2024-04-08 12:00 | American Association for Cancer Research Meeting - Abstract Number: 1927/5 |
| 2024-04-08 12:00 | American Association for Cancer Research Meeting - Abstract Number: 1924/2 |
| 2024-04-07 16:45 | American Association for Cancer Research Meeting - Abstract Number: ND03 |
| 2024-04-07 16:30 | American Association for Cancer Research Meeting - Abstract Number: 581/4 |
| 2024-03-06 14:10 | TD Cowen Health Care Conference |
| 2024-02-26 16:30 | Q4 2023 Earnings Call |
| 2024-02-25 | Q4 2023 Earnings Release After hours |
Annual results
| Fiscal Period | December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 29,4 28,7 2.35% | 35,4 27,9 26.79% | 11,6 11,8 -2.05% | 1,62 | 3,23 | 21,9 |
|
EBITDA Million USD | Released Forecast Spread | -185 -173 -7.04% | -253 -263 3.72% | -481 -424 -13.47% | -637 | -715 | -777 |
|
EBIT Million USD | Released Forecast Spread | -188 -181 -3.61% | -258 -269 4.04% | -487 -433 -12.56% | -647 | -719 | -727 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -187 -182 -2.99% | -249 -265 5.88% | -440 -395 -11.25% | -566 | -674 | -682 |
|
Net income Million USD | Released Forecast Spread | -187 -183 -2.45% | -249 -262 5.11% | -436 -392 -11.32% | -566 | -666 | -694 |
|
EPS USD | Released Forecast Spread | -2,57 -2,52 -2.01% | -3,08 -3,28 6.06% | -3,86 -3,48 -10.99% | -3,47 | -3,89 | -3,88 |
| Announcement Date | 28/02/22 | 27/02/23 | 26/02/24 | - |
Quarterly results
| Fiscal Period | Juni | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 3,36 6,34 -47.04% | 15,3 7,80 96.47% | 7,01 2,94 138.77% | 3,82 1,56 144.74% | 0,00 0,86 - | 0,74 1,20 -38.17% | 0,00 0,67 - | 0,00 0,81 - | 0,81 | 0,81 | 1,00 | 1,00 | 1,00 | 1,00 |
|
EBITDA Million USD | Released Forecast Spread | -178 | -139 -160 13.28% | -155 -152 -2.11% | -172 | -196 | -200 | -201 | -203 | -204 | |||||
|
EBIT Million USD | Released Forecast Spread | -76,5 -68,1 -12.43% | -61,7 -72,6 15% | -75,2 -78,1 3.71% | -109 -88,9 -22.33% | -123 -115 -7.3% | -180 -129 -39.54% | -141 -139 -1.41% | -157 -148 -6.12% | -167 | -185 | -183 | -185 | -188 | -191 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -73,6 -67,8 -8.66% | -56,6 -72,3 21.63% | -68,1 -77,5 12.18% | -98,3 -86,2 -14.03% | -112 -109 -2.58% | -161 -117 -37.59% | -116 -118 1.33% | -133 -128 -4.15% | -149 | -168 | -169 | -172 | -175 | -178 |
|
Net income Million USD | Released Forecast Spread | -73,3 -69,8 -5.05% | -56,5 -70,9 20.25% | -68,1 -78,0 12.66% | -98,3 -86,8 -13.28% | -108 -110 1.61% | -162 -120 -34.59% | -116 -119 2.6% | -133 -128 -4% | -150 | -168 | -168 | -172 | -177 | -180 |
|
EPS USD | Released Forecast Spread | -0,87 -0,85 -2.71% | -0,63 -0,81 22.36% | -0,72 -0,82 11.69% | -0,92 -0,83 -10.65% | -0,99 -1,02 2.53% | -1,14 -0,86 -32.31% | -0,70 -0,74 4.93% | -0,81 -0,78 -3.93% | -0,90 | -0,99 | -1,00 | -1,02 | -1,03 | -1,05 |
| Announcement Date | 07/11/22 | 27/02/23 | 08/05/23 | 08/08/23 | 06/11/23 | 26/02/24 | 08/05/24 | 07/08/24 | - | - | - | - | - | - |
More events
Past sector events for Revolution Medicines, Inc.
| 2024-09-09 16:01 | ABIVAX: Q2 2024 Earnings Release |
| 2024-09-05 02:00 | GENUS PLC: Q4 2024 Earnings Release |
| 2024-08-29 | JOINN LABORATORIES(CHINA)CO.,LTD.: Q2 2024 Earnings Release |
| 2024-08-29 02:00 | BIOARCTIC AB: Q2 2024 Earnings Release |
| 2024-08-28 19:27 | MESOBLAST LIMITED: Q4 2024 Earnings Release |
| 2024-08-28 | R&G PHARMASTUDIES CO., LTD.: Q2 2024 Earnings Release |
| 2024-08-28 | MORPHOSYS AG: Q2 2024 Earnings Release |
| 2024-08-28 02:00 | PURETECH HEALTH PLC: Q2 2024 Earnings Release |
| 2024-08-27 | HANGZHOU TIGERMED CONSULTING CO., LTD: Q2 2024 Earnings Release |
| 2024-08-27 04:00 | OCULIS HOLDING AG: Q2 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- RVMD Stock
- Calendar Revolution Medicines, Inc.
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition